WELLESLEY, Mass., Feb. 8 /PRNewswire-FirstCall/ -- Coley Pharmaceutical Group, Inc. , today announced that the company will host an investor conference call at 4:30 p.m. Eastern Time on February 15, 2007 to discuss the company's fourth quarter and fiscal year 2006 results.
To access the live audio broadcast or the subsequent archived recording of the call, please visit the Investor Center section of the Coley website at www.coleypharma.com. Please log onto Coley's website several minutes prior to the start of the call to ensure adequate time for any software download that may be required. A replay of this webcast will be available through March 1, 2007.
Investors may participate in the conference call by dialing either +1-866-713-8562 in the U.S. or +1-617-597-5310 outside the U.S. and typing in the passcode 24291559. A replay of this call will be available at +1-888-286- 8010 (U.S.) or +1-617-801-6888 (international) using the passcode 60397604 until March 1, 2007.
The webcast is also being distributed through the Thomson StreetEvents Network to both institutional and individual investors. Individual investors can listen to the call at www.fulldisclosure.com and institutional investors can access the call via www.streetevents.com.
About Coley Pharmaceutical Group
Coley Pharmaceutical Group, Inc. is an international biopharmaceutical company, headquartered in Wellesley, Massachusetts, USA, that discovers and develops TLR Therapeutics(TM), a new class of investigational drug candidates that direct the human immune system to fight cancers, infectious diseases, asthma and allergy. Coley has established a pipeline of TLR Therapeutic product candidates currently advancing through clinical development either independently or with partners, and additional product candidates in preclinical development. Coley has product development, research and license agreements with Pfizer, sanofi-aventis, Novartis Vaccines (formerly Chiron), GlaxoSmithKline and the United States government. For further information on Coley Pharmaceutical Group please visit www.coleypharma.com.
Coley Pharmaceutical GroupCONTACT: Susan Hager, Senior Director, Investor Relations and CorporateCommunications, of Coley Pharmaceutical Group, +1-781-431-9079, orshager@coleypharma.com; or Karen L. Bergman, +1-650-575-1509, orkbergman@bccpartners.com, or Michelle Corral, +1-415-794-8662, ormcorral@bccpartners.com, both of BCC Partners (US), for ColeyPharmaceutical Group
Web site: http://www.coleypharma.com/
